Acknowledging the need for strengthening cooperation between three Baltic countries to exchange of experiences and establish common approaches in tuberculosis (TB) control in Baltics, as well as to advocate for TB priority areas in countries, the first TB symposium was organised in 2016; Since then Baltic TB symposiums in Riga have become highly anticipated events, each year connecting over 75 participants and high level field experts - TB clinicians, nurses, public health, social service, NGO and patient representatives, as well as the policy makers. 

The 4th Baltic States Tuberculosis Symposium will be organized in May 2021.

The Symposium will be devoted to the Baltic States perspectives towards achieving the global targets for TB: reviewing the progress of countries, assessing the successes in implementing the Action plan for TB control in the WHO European region 2016-2020 in Baltic countries, identifying the gaps and challenges achieving the end-TB milestones for 2020 and the Sustainable Development Goals 2030, as well as discussing the progress and interventions towards improving the situation in the Baltic region's priority areas. 

Agenda of the Symposium will include topics on strengthening the inter-sectoral collaboration on TB, HIV and Hepatitis C, latent TB infection treatment and management, the importance of monitoring and evaluation in countries, as well as updates in countries on drug-resistant TB treatment with new drugs and treatment regimens and patient-centered care approaches, including video-observed treatment.

3rd Baltic States Symposium Strengthening the people-centred model of tuberculosis care for better diagnosis and treatment outcomes

November 23-24, 2018

The third Baltic States Symposium was devoted to people-centred model of drug-resistant tuberculosis (DR-TB) care for achieving better treatment outcomes. The main objective of the Symposium was to develop a common memorandum of understanding on how to achieve a best-adapted model of care in all three Baltic countries and a list of the most effective activities to achieve this goal. 
The program included digital health solutions for treatment adherence and TB patient empowerment, nursing process - patient education, psycho-emotional support, stigma reduction, upcoming WHO guidelines on the management of DR-TB as well as latent TB infection diagnostic and treatment and molecular methods for TB diagnostic.79 participants and facilitators from Latvia, Lithuania, Estonia, The Netherlands, Germany and the United Kingdom attended the symposium. 

2nd International Baltic Symposium Management of TB/HIV co-infected patients: challenges and opportunities to End TB Strategy

May 19-20, 2017

2nd Baltic States symposium was organized jointly for TB and HIV specialists to introduce the latest developments in management of TB/HIV co-infected patients and prepare a country-specific list of priority actions for adaptation of these developments in Baltic countries.  

Outline of the symposium included latent TB infection diagnostics and treatment experiences in European countries for HIV infected persons, including children, integrated care for TB/HIV affected persons, the role of pharmacovigilance, and country updates in the introduction of new anti TB drugs. 
75 participants and facilitators from Denmark, Lithuania, Estonia, Latvia, Italy, and The Netherlands attended the event. 

1st Baltic States symposium Introduction of new and repurposed drugs in the programmatic management of DR-TB – from science to practice

May 23-24, 2016 

1st Baltic States symposium was a major step towards scaling up common strategies in the Baltic States in safe, rational and effective use of TB  novel drugs, as well as applying new practices and approaches in the framework of programmatic management of DR-TB.

Objectives of the symposium were to provide an update on current evidence and WHO policy recommendations on the use of new and re-purposed drugs; to discuss the programmatic introduction and future positioning of new drugs – TB patient triage concept, future regimen design, treatment duration; to share experiences and practices from countries using new and re-purposed drugs for adults and children and to decide on common strategies in Baltic states on future improvements of M/XDR-TB management.

More than 70 participants attended the Symposium. Most of them were TB doctors from various settings, including regional hospitals, outpatient departments, penitentiary systems and laboratories, involved in the introduction of new TB drugs in their respective institutions.